ReviewPharmacy (Basel, Switzerland)2020
Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness.
Review in Pharmacy (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- Digital and Biomarker-Based Monitoring for Schizophrenia-Treatment Adherence.Neuropsychopharmacology reports · 2026Review
- Improving medication adherence in cardiovascular disease.The British journal of cardiology · 2026Article
- Barriers to translating continuous monitoring technologies for preventative medicine.Nature biomedical engineering · 2025Review
- Wearable biomolecular sensing nanotechnologies in chronic disease management.Nature nanotechnology · 2025Review
- Capsule robots for the monitoring, diagnosis, and treatment of intestinal diseases.Materials today. Bio · 2024Review
- Medical Measures in Hypertensives Considered Resistant.American journal of hypertension · 2024Article
- Advances and Opportunities of Mobile Health in the Postpandemic Era: Smartphonization of Wearable Devices and Wearable Deviceization of Smartphones.JMIR mHealth and uHealth · 2024Article
- Review of glaucoma medication adherence monitoring in the digital health era.The British journal of ophthalmology · 2023Review
- Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Bibliometric analysis and evidence of clinical efficacy and safety of digital pills.Frontiers in pharmacology · 2023Review
- Use of an Ingestible, Sensor-Based Digital Adherence System to Strengthen the Therapeutic Relationship in Serious Mental Illness.JMIR mental health · 2022Article
- A Review of Digital Health and Biotelemetry: Modern Approaches towards Personalized Medicine and Remote Health Assessment.Journal of personalized medicine · 2022Review
- Digital Pills with Ingestible Sensors: Patent Landscape Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Psychiatry in the Digital Age: A Blessing or a Curse?International journal of environmental research and public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia.
methodsLiterature searches were conducted in July 2019 in the PubMed database.
resultsIn small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of "mild disease". Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use.
conclusionsA medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.